InvestorsHub Logo
Followers 116
Posts 1877
Boards Moderated 0
Alias Born 11/22/2017

Re: longfellow95 post# 214057

Monday, 02/11/2019 3:57:27 PM

Monday, February 11, 2019 3:57:27 PM

Post# of 700676
Longfellow95,

I don't know if these subjects received Bev because that caps survival after recurrence at 9 or 10 months...



Bevacizumab? (Avastin) : imo they received Bev. See this:https://pbs.twimg.com/media/DzIw-UjWoAAUuAf.jpg

More info:UCLA Health

For recurrent glioblastoma, immunotherapy before surgery appears to help more than afterward.

UCLA-led research could be step toward new therapy for hard-to-treat brain cancer
02/11/2019
https://www.uclahealth.org/for-recurrent-glioblastoma-immunotherapy-before-surgery-appears-to-help-more-than-afterward

“This isn’t a very big study, and our data need to be replicated, but we have a foot in the door,” Cloughesy said. “We have found a way to use these checkpoint inhibitors in glioblastoma that we previously thought were ineffective. We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it.”




The team is now testing the immunotherapy in combination with vaccines and other checkpoint inhibitors.



And this:

Article | Published: 11 February 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
https://www.nature.com/articles/s41591-018-0337-7

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News